Resultats globals: 13 registres trobats en 0.02 segons.
Articles, 13 registres trobats
Articles 13 registres trobats  1 - 10següent  anar al registre:
1.
6 p, 870.5 KB Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C / Notario, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cerdà, Gabriela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Muñoz-Mármol, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sánchez-Céspedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Costa, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mate, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. [...]
2023 - 10.3389/fonc.2023.1239000
Frontiers in Oncology, Vol. 13 (october 2023)  
2.
9 p, 902.3 KB Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients : an exploratory longitudinal study / Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ; Garcia-Campelo, R. (Complejo Hospitalario Universitario de A Coruña) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Isla, D. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Gonzalez-Larriba, J.L. (Hospital Clínico San Carlos (Madrid)) ; Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; De-Castro, J. (Hospital Universitario La Paz (Madrid)) ; Domine, M. (Hospital Universitario Fundación Jiménez Díaz) ; Lianes, P. (Hospital de Mataró. Consorci Sanitari del Maresme) ; Artal, A. (Hospital Universitario Miguel Servet (Saragossa)) ; Remon, J. (CIOCC Barcelona - HM Delfos) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Garrido, P. (Hospital Universitario Ramón y Cajal (Madrid)) ; Universitat Autònoma de Barcelona
Little is known about the impact of sex on lung cancer patients from the psychological, economic and social perspectives. This study was designed to explore the psychosocial and economic impact according to sex of metastatic non-small cell lung cancer (mNSCLC) in patients and caregivers. [...]
2020 - 10.1186/s40359-020-00489-z
BMC Psychology, Vol. 8 Núm. 1 (december 2020) , p. 123  
3.
17 p, 534.5 KB COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer / Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Barlesi, Fabrice (Gustave Roussy) ; Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Chu, Quincy (Cross Cancer Institute) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ; Dakhil, Shaker (Cancer Center of Kansas) ; Camidge, D (University of Colorado Anschutz Medical Campus) ; Winzer, Leanne (AstraZeneca) ; Soo-Hoo, Yee (AstraZeneca) ; Cooper, Zachary A. (AstraZeneca) ; Kumar, Rakesh (AstraZeneca) ; Bothos, John (AstraZeneca) ; Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ; Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227  
4.
13 p, 368.5 KB Dynamic changes in circulating tumor assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in / Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ; Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ; Pardo Aranda, Nuria (Vall d'Hebron Institut d'Oncologia) ; Callejo, Ana (Vall d'Hebron Institut d'Oncologia) ; Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ; Valdivia, Augusto (Vall d'Hebron Institut d'Oncologia) ; Priano, Ilaria (Vall d'Hebron Institut d'Oncologia) ; Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ; Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ; Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ; Lenza, Laura (Vall d'Hebron Institut d'Oncologia) ; Soleda, Mireia (Vall d'Hebron Institut d'Oncologia) ; Gonzalo-Ruiz, Javier (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Sansó, Miriam (Institut d'Investigació Sanitària Illes Balears) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Amat, Ramon (Vall d'Hebron Institut d'Oncologia) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. [...]
2023 - 10.1002/1878-0261.13409
Molecular Oncology, Vol. 17 (march 2023) , p. 779-791  
5.
12 p, 3.1 MB Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer / Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martinez-Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pros, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Identifying molecular oncogenic drivers is crucial for precision oncology. Genetic rearrangements, including gene fusions and gene amplification, involving and activating receptor tyrosine kinases (RTKs) are recurrent in solid tumors, particularly in non-small cell lung cancer. [...]
2022 - 10.1016/j.ctrv.2022.102430
Cancer Treatment Reviews, Vol. 109 (september 2022) , p. 102430  
6.
8 p, 892.3 KB Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors : The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies / Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Notario, Lucia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hierro, Cinta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Estival, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Saigí, María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered "undruggable" for decades, specific KRAS G12C covalent inhibitors have recently emerged, although their promising results are limited to a subset of patients. [...]
2021 - 10.3389/fonc.2021.793121
Frontiers in Oncology, Vol. 11 (13 2021) , p. 793121  
7.
13 p, 2.2 MB Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Institut Català d'Oncologia) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086  
8.
1 p, 789.3 KB Correction : Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Institut Català d'Oncologia) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
2019 - 10.18632/oncotarget.26855
Oncotarget, Vol. 10 (april 2019) , p. 2576  
9.
15 p, 955.9 KB SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Trigo, J. M. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; García García, Yolanda (Universitat Autònoma de Barcelona. Departament de Medicina) ; Guirado, M. (Hospital General Universitario de Elche) ; Provencio, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. [...]
2018 - 10.1007/s12094-018-1978-1
Clinical & Translational Oncology, Vol. 21 (november 2018) , p. 3-17  
10.
12 p, 1.4 MB Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC / Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ; Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ; Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ; Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Drozdowskyj, Ana (Pivotal, Madrid) ; Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ; Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ; Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Sanchez, Jose Miguel (Hospital Universitario de la Princesa (Madrid)) ; Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ; Teixidó, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ; Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ; Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ; Aguirre, Itziar de (Institut Germans Trias i Pujol) ; Queralt, C (Institut Germans Trias i Pujol) ; Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol) ; Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ; Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ; Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Bivona, Trever (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12  

Articles : 13 registres trobats   1 - 10següent  anar al registre:
Vegeu també: autors amb noms similars
2 Carcereny, E.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.